Pfizer Inc.
PFE
$28.32
-0.81%
Pfizer Inc. is a global pharmaceutical giant operating in the Drug Manufacturers industry. It is defined by its massive scale and diversified portfolio of prescription drugs and vaccines, with a core narrative centered on its strategic shift and resilience following recent challenges.…
PFE
Pfizer Inc.
$28.32
Related headlines
Investment Opinion: Should I buy PFE Today?
Based on a synthesis of the data, the objective assessment tilts towards a Hold rating for PFE. The stock is not a clear 'Buy' due to the significant earnings shock and revenue decline, which create near-term uncertainty. However, it is also not a 'Sell' given its low forward valuation, high dividend yield, and strong recent relative performance. The current price near its 52-week high suggests much of the near-term positive news may be reflected. Investors should await clearer signs of earnings stabilization and pipeline execution before establishing new positions.
Sign up to view all
PFE 12-Month Price Forecast
The analysis yields a neutral stance. Compelling value (low forward P/E, high yield) is counterbalanced by clear fundamental deterioration (negative earnings, revenue decline). The path forward depends heavily on the company's ability to stabilize profits and execute its pipeline, making the near-term outlook uncertain.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer Inc.'s 12-month outlook, with a consensus price target around $36.82 and implied upside of +30.0% versus the current price.
Average Target
$36.82
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$23 - $37
Analyst target range
Wall Street analyst coverage includes 11 firms providing estimates. The consensus for future performance includes an average estimated EPS of $2.22 and average estimated revenue of $51.8B. Recent institutional ratings show a mix of Buy and Neutral/Equal Weight actions, with firms like Guggenheim and HSBC maintaining Buy ratings, while Morgan Stanley and B of A Securities have Neutral or Equal Weight stances.
Bulls vs Bears: PFE Investment Factors
Pfizer presents a classic value-income versus growth challenge. The bull case is built on a low forward P/E, a high dividend yield, and recent positive pipeline developments. The bear case highlights severe recent earnings volatility, a declining top line, and significant competitive and patent-related headwinds. The stock's recent strong performance may have priced in near-term optimism.
Bullish
- Strong Relative Performance: Stock up 12.8% in 3 months, significantly outperforming the S&P 500.
- Attractive Forward Valuation: Forward P/E of 9.95 is low, suggesting potential for re-rating.
- High Dividend Yield: Yield of ~6.9% provides substantial income and downside cushion.
- Solid Financial Health: Strong free cash flow of $9.1B and manageable debt-to-equity of 0.78.
Bearish
- Severe Q4 Profitability Shock: Q4 2025 net loss of $1.65B with a negative net margin of -9.4%.
- Revenue Decline: Recent quarterly revenue declined 1.16% year-over-year.
- High Payout Ratio: Dividend payout ratio over 125% raises sustainability concerns.
- Patent Cliff & Competition: Key drug expirations and intense competition in new markets like obesity.
PFE Technical Analysis
Overall Assessment: The stock has shown a volatile but ultimately positive trend over the last six months, rising from around $27 in early October 2025 to close at $28.08 on March 31, 2026, representing a 6-month gain of 3.69%. The price has recently broken out of a consolidation range, approaching its 52-week high. Short-term Performance: Over the past month, the stock gained 1.56%, significantly outperforming the S&P 500, which fell 5.25%, as indicated by a strong relative strength of 6.81. The 3-month performance is even more robust, with a 12.77% gain against the S&P 500's 4.63% decline. Current Position: The current price of $28.08 is near the top of its 52-week range of $20.92 to $28.31, sitting just 0.8% below the yearly high. The stock's beta of 0.412 indicates it has been less volatile than the broader market during this period.
Beta
0.41
0.41x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$21-$29
Price range past year
Annual Return
+14.7%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | +6.5% | -3.6% |
| 3m | +12.5% | -4.0% |
| 6m | +3.5% | -2.0% |
| 1y | +14.7% | +16.2% |
| ytd | +12.5% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Revenue & Profitability: The company's most recent quarterly revenue of $17.56B showed a year-over-year decline of 1.16%. Profitability was severely impacted in Q4 2025, with a net loss of $1.65B and a negative net margin of -9.4%, a stark contrast to the positive net income and margins reported in the preceding three quarters of 2025. Financial Health: The balance sheet appears manageable with a debt-to-equity ratio of 0.78. The company maintains a current ratio of 1.16, indicating adequate short-term liquidity, and generates substantial free cash flow, with a TTM figure of $9.08B. Operational Efficiency: Return on Equity (ROE) stands at 8.99%, which is modest, while Return on Assets (ROA) is 5.68%. The quarterly gross margin remains healthy at approximately 70%, but operating income was significantly pressured in the latest quarter due to large other expenses.
Quarterly Revenue
$17.6B
2025-12
Revenue YoY Growth
-0.01%
YoY Comparison
Gross Margin
+0.69%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Valuation Level: Given the positive trailing twelve-month net income, the primary valuation metric is the trailing P/E ratio, which is 18.21. This suggests the market is valuing the company at a moderate earnings multiple. The forward P/E of 9.95 is significantly lower, reflecting analyst expectations for improved future earnings. Peer Comparison: Industry average valuation metrics are not provided in the data for a direct comparison. However, the company's Price-to-Sales ratio is 2.26 and its EV/EBITDA is 13.76, which can be contextual benchmarks for the sector.
PE
18.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -21x~1666x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Pfizer's primary risks are operational and financial. The Q4 2025 net loss of $1.65B, driven by $5.33B in 'other expenses,' indicates significant one-time charges or write-downs, creating earnings volatility and uncertainty. The high dividend payout ratio of 125.8% is unsustainable if earnings do not recover, posing a risk to the attractive yield that supports the stock price. Furthermore, the company faces industry-wide risks including patent expirations for key drugs, intense competition in growth areas like obesity treatments, and the inherent uncertainty of clinical trial outcomes, as seen with the mixed results for the Valneva-Pfizer Lyme vaccine. While the balance sheet is currently stable, prolonged earnings pressure could strain financial flexibility.